Durvalumab and tremelimumab for pediatric malignancies

Study identifier:D419EC00001

ClinicalTrials.gov identifier:NCT03837899

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or in Combination with Tremelimumab in Pediatric Patients with Advanced Solid Tumors and Hematological Malignancies.

Medical condition

Pediatric Cancer

Phase

Phase 1/2

Healthy volunteers

No

Study drug

Durvalumab / Tremelimumab Combination Therapy

Sex

All

Actual enrollment

158

Study type

Interventional

Age

0 Years - 18 Years

Date

Study Start Date: 07 Mar 2019
Estimated Primary Completion Date: 23 Jun 2023
Estimated Study Completion Date: 22 Dec 2023

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2022 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria